Opus Genetics Capital Expenditures (CapEx) Growth & History (IRD)
Opus Genetics's capital expenditures (capex) was $0 for fiscal 2020.
View full Opus Genetics company overviewOpus Genetics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2020 | 2020-12-31 | $0 | −$25,000 | — |
| 2019 | 2019-12-31 | $25,000 | −$14,224 | −36.26% |
| 2018 | 2018-12-31 | $39,224 | −$35,944 | −47.82% |
| 2017 | 2017-12-31 | $75,168 | $66,502 | +767.39% |
| 2016 | 2016-12-31 | $8,666 | −$53,636 | −86.09% |
| 2015 | 2015-12-31 | $62,302 | $21,053 | +51.04% |
| 2014 | 2014-12-31 | $41,249 | −$8,900 | −17.75% |
| 2013 | 2013-12-31 | $50,149 | — | — |
| 2011 | 2011-12-31 | $16,047 | $10,801 | +205.89% |
| 2010 | 2010-12-31 | $5,246 | −$13,124 | −71.44% |
| 2009 | 2009-12-31 | $18,370 | — | — |
Opus Genetics quarterly capital expenditures (capex)
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q4 2019 | 2019-12-31 | $5,617 | $5,617 | — |
| Q3 2019 | 2019-09-30 | $0 | −$35,731 | — |
| Q2 2019 | 2019-06-30 | $6,202 | $5,229 | +537.41% |
| Q1 2019 | 2019-03-31 | $13,181 | $10,661 | +423.06% |
| Q4 2018 | 2018-12-31 | $0 | −$53,799 | — |
| Q3 2018 | 2018-09-30 | $35,731 | $32,272 | +932.99% |
| Q2 2018 | 2018-06-30 | $973 | −$12,972 | −93.02% |
| Q1 2018 | 2018-03-31 | $2,520 | −$1,445 | −36.44% |
| Q4 2017 | 2017-12-31 | $53,799 | $53,396 | +13249.63% |
| Q3 2017 | 2017-09-30 | $3,459 | $2,707 | +359.97% |
| Q2 2017 | 2017-06-30 | $13,945 | $11,030 | +378.39% |
| Q1 2017 | 2017-03-31 | $3,965 | −$631 | −13.73% |
| Q4 2016 | 2016-12-31 | $403 | −$9,400 | −95.89% |
| Q3 2016 | 2016-09-30 | $752 | −$39,359 | −98.13% |
| Q2 2016 | 2016-06-30 | $2,915 | −$1,538 | −34.54% |
| Q1 2016 | 2016-03-31 | $4,596 | −$3,339 | −42.08% |
| Q4 2015 | 2015-12-31 | $9,803 | −$1,292 | −11.64% |
| Q3 2015 | 2015-09-30 | $40,111 | $24,171 | +151.64% |
| Q2 2015 | 2015-06-30 | $4,453 | −$5,990 | −57.36% |
| Q1 2015 | 2015-03-31 | $7,935 | $4,164 | +110.42% |
| Q4 2014 | 2014-12-31 | $11,095 | $7,405 | +200.68% |
| Q3 2014 | 2014-09-30 | $15,940 | −$28,910 | −64.46% |
| Q2 2014 | 2014-06-30 | $10,443 | $9,443 | +944.30% |
| Q1 2014 | 2014-03-31 | $3,771 | $3,162 | +519.21% |
| Q4 2013 | 2013-12-31 | $3,690 | — | — |
| Q3 2013 | 2013-09-30 | $44,850 | — | — |
| Q2 2013 | 2013-06-30 | $1,000 | — | — |
| Q1 2013 | 2013-03-31 | $609 | $609 | — |
| Q1 2012 | 2012-03-31 | $0 | $0 | — |
| Q4 2011 | 2011-12-31 | $11,636 | — | — |
| Q3 2011 | 2011-09-30 | $2,257 | $1,510 | +202.14% |
| Q2 2011 | 2011-06-30 | $2,154 | — | — |
| Q1 2011 | 2011-03-31 | $0 | — | — |
| Q3 2010 | 2010-09-30 | $747 | — | — |
Opus Genetics capital expenditures (capex) trends
Over the last five fiscal years, Opus Genetics's capital expenditures (capex) decreased from $62,302 to $0, a change of −$62,302. The latest reported quarter, Q4 2019, shows $5,617.
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Opus Genetics source filings ↗